Sera Prognostics (NASDAQ:SERA) Issues Quarterly Earnings Results

Sera Prognostics (NASDAQ:SERA) issued its quarterly earnings data on Wednesday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports.

Sera Prognostics Price Performance

NASDAQ SERA traded up $0.06 on Wednesday, reaching $4.14. The company had a trading volume of 57,077 shares, compared to its average volume of 142,782. Sera Prognostics has a 1 year low of $3.84 and a 1 year high of $12.36. The firm has a 50-day moving average of $5.15 and a 200-day moving average of $6.62. The firm has a market capitalization of $139.82 million, a PE ratio of -4.18 and a beta of 0.89.

Insider Activity

In other Sera Prognostics news, Director Joshua Phillips sold 12,163 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the transaction, the director now directly owns 2 shares of the company’s stock, valued at $12.78. This represents a 99.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Robert Gardner Harrison sold 14,209 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the transaction, the insider now owns 116,837 shares of the company’s stock, valued at approximately $863,425.43. This trade represents a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,877 shares of company stock worth $480,677 over the last 90 days. Company insiders own 15.80% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.